Managers / Q3 2022 · view latest →
Altium Capital Management LLC
CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711
Reported Value
$273M
Q3 2022
Positions
134
Filings on Record
25
2019–present window
Filed
Nov 14, 2022
original filing
Summary
Altium Capital Management LLC reported $273M in U.S.-listed holdings across 134 positions for Q3 2022.
Its largest position, BLU, represents 4.4% of the portfolio.
Compared with Q2 2022, the fund opened 41 new positions and exited 32.
Portfolio Metrics
Turnover
+30.4%
vs prior filed quarter
Top-10 Concentration
+26.4%
share of reported value
Largest Position
+4.4%
Bellus Health
New / Exited
41 / 32
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 72.0% · $196M
- Other · 25.7% · $70M
- ADR · 1.7% · $5M
- Equity WRT · 0.6% · $2M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| GUARDANT HEALTH INC | NEW | +100.0K | 100.0K | +$5M | $5M |
| AKROAKERO THERAPEUTICS INC | NEW | +140.0K | 140.0K | +$5M | $5M |
| PLRXPLIANT THERAPEUTICS INC | NEW | +215.0K | 215.0K | +$4M | $4M |
| BIOATLA INC | NEW | +553.0K | 553.0K | +$4M | $4M |
| RYTMRHYTHM PHARMACEUTICALS INC | NEW | +170.0K | 170.0K | +$4M | $4M |
| VRNAVERONA PHARMA PLC | NEW | +404.0K | 404.0K | +$4M | $4M |
| ASTRIA THERAPEUTICS INC | NEW | +445.0K | 445.0K | +$4M | $4M |
| BIOLINERX LTD | NEW | +4.15M | 4.15M | +$4M | $4M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2022
118 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | BLUBELLUS HEALTH INC NEWhistory → | COM NEW | 4.38% | $12M | 1.13M |
| 2 | CHINOOK THERAPEUTICS INC | COM | 3.78% | $10M | 525.0K |
| 3 | CHEMOCENTRYX INC | COM | 3.03% | $8M | 160.0K |
| 4 | PEPPERLIME HEALTH ACQUSTN CO | CLASS A ORD SHS · *W EXP 10/01/202 | 2.70% | $7M | 1.10M |
| 5 | ADMAADMA BIOLOGICS INChistory → | COM | 2.57% | $7M | 2.88M |
| 6 | CYMABAY THERAPEUTICS INC | COM | 2.25% | $6M | 1.75M |
| 7 | INSMINSMED INChistory → | COM PAR $.01 | 2.12% | $6M | 268.0K |
| 8 | NOCTURNE ACQUISITION CORP | ORDINARY SHARES · RIGHT 12/26/2025 | 1.90% | $5M | 1.00M |
| 9 | GKOSGLAUKOS CORPhistory → | COM | 1.89% | $5M | 97.0K |
| 10 | AKROAKERO THERAPEUTICS INChistory → | COM | 1.75% | $5M | 140.0K |
| 11 | INTRA-CELLULAR THERAPIES INC | COM | 1.71% | $5M | 100.0K |
| 12 | XTNTXTANT MED HLDGS INChistory → | COM NEW | 1.65% | $4M | 6.25M |
| 13 | PLRXPLIANT THERAPEUTICS INChistory → | COM | 1.65% | $4M | 215.0K |
| 14 | ESPRESPERION THERAPEUTICS INC NEhistory → | COM | 1.62% | $4M | 659.9K |
| 15 | BIOATLA INC | COM | 1.56% | $4M | 553.0K |
| 16 | ILMNILLUMINA INChistory → | COM | 1.54% | $4M | 22.0K |
| 17 | RYTMRHYTHM PHARMACEUTICALS INChistory → | COM | 1.53% | $4M | 170.0K |
| 18 | VRNAVERONA PHARMA PLChistory → | SPONSORED ADS | 1.51% | $4M | 404.0K |
| 19 | KARYOPHARM THERAPEUTICS INC | COM | 1.50% | $4M | 750.0K |
| 20 | ASTRIA THERAPEUTICS INC | COM | 1.47% | $4M | 445.0K |
| 21 | EUCRATES BIOMEDICAL ACQU COR | SHS · *W EXP 10/23/202 | 1.47% | $4M | 533.3K |
| 22 | ANGOANGIODYNAMICS INChistory → | COM | 1.46% | $4M | 195.0K |
| 23 | BIOLINERX LTD | SPONSORED ADS | 1.41% | $4M | 4.15M |
| 24 | KARUNA THERAPEUTICS INC | COM | 1.40% | $4M | 17.0K |
| 25 | RMDRESMED INChistory → | COM | 1.36% | $4M | 17.0K |
| 26 | NANOSTRING TECHNOLOGIES INC | COM | 1.31% | $4M | 280.0K |
| 27 | QDELQUIDELORTHO CORPhistory → | COM | 1.31% | $4M | 50.0K |
| 28 | GHGUARDANT HEALTH INChistory → | COM | 1.30% | $4M | 66.0K |
| 29 | MYGNMYRIAD GENETICS INChistory → | COM | 1.30% | $4M | 186.0K |
| 30 | INGNINOGEN INChistory → | COM | 1.30% | $4M | 146.0K |
| 31 | AKOYA BIOSCIENCES INC | COM | 1.28% | $3M | 296.0K |
| 32 | PRCTPROCEPT BIOROBOTICS CORPhistory → | COM | 1.23% | $3M | 81.0K |
| 33 | EIGER BIOPHARMACEUTICALS INC | COM | 1.21% | $3M | 440.0K |
| 34 | KROSKEROS THERAPEUTICS INChistory → | COM | 1.21% | $3M | 88.0K |
| 35 | NTRANATERA INChistory → | COM | 1.21% | $3M | 75.0K |
| 36 | ATECALPHATEC HLDGS INChistory → | COM NEW | 1.10% | $3M | 342.0K |
| 37 | NEVRO CORP | COM | 1.09% | $3M | 64.0K |
| 38 | LNTHLANTHEUS HLDGS INChistory → | COM | 1.08% | $3M | 42.0K |
| 39 | SIBNSI-BONE INChistory → | COM | 1.07% | $3M | 167.0K |
| 40 | VERASTEM INC | COM | 0.93% | $3M | 3.00M |
| 41 | TURMERIC ACQUISITION CORP | CL A · *W EXP 10/08/202 | 0.93% | $3M | 338.7K |
| 42 | CTI BIOPHARMA CORP | COM | 0.91% | $2M | 427.0K |
| 43 | AVIDITY BIOSCIENCES INC | COM | 0.90% | $2M | 150.0K |
| 44 | TWSTTWIST BIOSCIENCE CORP | COM | 0.88% | $2M | 68.0K |
| 45 | SARISSA CAPITAL ACQUISITN CO | CL A · *W EXP 10/23/202 | 0.83% | $2M | 300.0K |
| 46 | IVERIC BIO INC | COM | 0.82% | $2M | 125.0K |
| 47 | KRMDKORU MEDICAL SYSTEMS INC | COM | 0.81% | $2M | 995.5K |
| 48 | ARCELLX INC | COMMON STOCK | 0.79% | $2M | 115.0K |
| 49 | OCULOCULAR THERAPEUTIX INC | COM | 0.79% | $2M | 517.1K |
| 50 | ADICET BIO INC | COM | 0.78% | $2M | 150.0K |
| 51 | INSPINSPIRE MED SYS INC | COM | 0.78% | $2M | 12.0K |
| 52 | 2SEVENTY BIO INC | COMMON STOCK | 0.75% | $2M | 140.0K |
| 53 | TG VENTURE ACQUISITION CORP | UNIT 08/15/2028 | 0.74% | $2M | 200.0K |
| 54 | NBIXNEUROCRINE BIOSCIENCES INC | COM | 0.74% | $2M | 19.0K |
| 55 | LAKESHORE ACQUISITION II COR | ORDINARY SHARES | 0.74% | $2M | 200.0K |
| 56 | JIYA ACQUISITION CORP | COM CL A | 0.73% | $2M | 200.0K |
| 57 | QUREUNIQURE NV | SHS | 0.72% | $2M | 105.0K |
| 58 | COLLCOLLEGIUM PHARMACEUTICAL INC | COM | 0.68% | $2M | 116.0K |
| 59 | VCELVERICEL CORP | COM | 0.68% | $2M | 80.0K |
| 60 | AFFIMED N V | COM | 0.68% | $2M | 900.0K |
| 61 | CARA THERAPEUTICS INC | COM | 0.66% | $2M | 193.0K |
| 62 | EYPTEYEPOINT PHARMACEUTICALS INC | COM NEW | 0.65% | $2M | 224.5K |
| 63 | MEDIWOUND LTD | ORD SHS | 0.65% | $2M | 1.28M |
| 64 | UNITY BIOTECHNOLOGY INC | COM | 0.62% | $2M | 4.27M |
| 65 | HLMNHILLMAN SOLUTIONS CORP | COM | 0.61% | $2M | 221.0K |
| 66 | TRVITREVI THERAPEUTICS INC | COM | 0.60% | $2M | 1.07M |
| 67 | GOSSGOSSAMER BIO INC | COM | 0.59% | $2M | 135.0K |
| 68 | CSTLCASTLE BIOSCIENCES INC | COM | 0.57% | $2M | 60.0K |
| 69 | ALKSALKERMES PLC | SHS | 0.57% | $2M | 70.0K |
| 70 | DIGITAL HEALTH ACQUISITION C | UNIT 11/02/2026 | 0.57% | $2M | 150.0K |
| 71 | AULT DISRUPTIVE TECHS CORP | COM · *W EXP 99/99/999 | 0.56% | $2M | 262.5K |
| 72 | FAT BRANDS INC | *W EXP 07/16/202 | 0.43% | $1M | 227.0K |
| 73 | QTRXQUANTERIX CORP | COM | 0.38% | $1M | 95.0K |
| 74 | RENOVACOR INC | COM · *W EXP 99/99/999 | 0.38% | $1M | 1.12M |
| 75 | LRMRLARIMAR THERAPEUTICS INC | COM | 0.38% | $1M | 320.0K |
| 76 | INDUSTRIAL HUMAN CAPITAL INC | COM · *W EXP 11/27/202 | 0.37% | $1M | 200.0K |
| 77 | WESTERN ACQSTN VENTURES CORP | UNIT 09/01/2026 | 0.37% | $1M | 100.0K |
| 78 | RELATIVITY ACQUISITION CORP | UNIT 02/10/2027 | 0.37% | $1M | 100.0K |
| 79 | MURPHY CANYON ACQUISITION CO | UNIT 01/25/2027 | 0.37% | $1M | 100.0K |
| 80 | BCLS ACQUISITION CORP | COM CL A | 0.37% | $1M | 100.0K |
| 81 | OPY ACQUISITION CORP I | COM CL A · *W EXP 09/22/202 | 0.37% | $998,000 | 150.0K |
| 82 | OMEGA ALPHA SPAC | CL A | 0.36% | $993,000 | 100.0K |
| 83 | ARYA SCIENCES ACQU CORP IV | CL A | 0.36% | $991,000 | 100.0K |
| 84 | AMLXAMYLYX PHARMACEUTICALS INC | COM | 0.36% | $985,000 | 35.0K |
| 85 | AEROVATE THERAPEUTICS INC | COM | 0.31% | $846,000 | 51.0K |
| 86 | COLISEUM ACQUISITION CORP | CLASS A ORD SHS · *W EXP 08/22/202 | 0.31% | $837,000 | 113.3K |
| 87 | POLISHED COM INC | *W EXP 06/02/202 | 0.28% | $763,000 | 6.10M |
| 88 | MUSCLE MAKER INC | COM | 0.24% | $666,000 | 1.77M |
| 89 | DDIDOUBLEDOWN INTERACTIVE CO LT | ADS | 0.21% | $562,000 | 60.9K |
| 90 | PALISADE BIO INC | COM | 0.20% | $559,000 | 5.64M |
| 91 | GSR II METEORA ACQUISITN COR | UNIT 02/24/2027 | 0.19% | $514,000 | 50.0K |
| 92 | COLOMBIER ACQUISITION CORP | CL A · *W EXP 99/99/999 | 0.18% | $490,000 | 66.7K |
| 93 | PEPGPEPGEN INC | COM | 0.13% | $363,000 | 40.0K |
| 94 | T2 BIOSYSTEMS INC | COM | 0.12% | $321,000 | 2.84M |
| 95 | RLMDRELMADA THERAPEUTICS INC | COM | 0.12% | $315,000 | 8.5K |
| 96 | WEARABLE DEVICES LTD | *W EXP 09/14/202 | 0.11% | $295,000 | 1.41M |
| 97 | BENITEC BIOPHARMA INC | COM | 0.09% | $245,000 | 658.8K |
| 98 | HARBOR CUSTOM DEVELOPMENT IN | *W EXP 10/04/202 · *W EXP 05/09/202 | 0.08% | $205,000 | 1.25M |
| 99 | TWIN VEE POWERCATS CO | COM | 0.06% | $165,000 | 67.8K |
| 100 | VIGLVIGIL NEUROSCIENCE INC | COM | 0.05% | $144,000 | 15.8K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $42M | 19 | May 1, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $25M | 18 | Feb 6, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $628,262 | 1 | Nov 4, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $42M | 24 | May 13, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2024 | $353M | 67 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $340M | 79 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $245M | 68 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $253M | 72 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $147M | 66 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $192M | 72 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $132M | 68 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $180M | 91 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $197M | 94 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $273M | 134 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $250M | 127 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $299M | 118 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $363M | 133 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $381M | 124 | Nov 17, 2021 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2021 | $431M | 135 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $360M | 124 | May 6, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $266M | 98 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.